Evaluation of Addition Of Sildenafil Citrate On Fetal Growth And Doppler Indices In Treatment of Pregnancy Induced Hypertension

Abstract

Pregnancy induced hypertension (PIH) is the most common complication during pregnancy and it affects up to 12% of pregnancies. It is the leading cause of maternal and fetal morbidity and mortality (1). Sildenafil is a potent and selective inhibitor of cGMP .which results in increased levels of cGMP, leading to smooth muscle relaxation thus mediating improved uteroplacental perfusion and increased fetal growth (12). Objectives:This study is to evaluate effect of sildenafil citrate on fetal growth and Doppler indices in treatment of pregnancy induced hypertension Setting:Department of Obstetrics &Gynecology, Beni-Suef University Hospital. Methods:Patients were divided into two groups: Group A (sildenafil group) were offered Sildenafil 20 mg t.i.d. with a plenty of fluids until delivery in addition to traditional treatment. Group B (Placebo group) received placebo drug with the same shape and texture as sildenafil citrate in addition to traditional treatment.Main outcome measures: Utero placental perfusion, fetal growth and maternal and fetal safety. Results: Sildenafil treatment was associated with a significant decrease of SBP between the two time points (P-value<0.001), a significant decrease of DBP between the two time points (P-value<0.001) and increase in estimated fetal weight by ultrasound (P<0.001). Conclusions: Despite limited data, overall there does not appear to be any severe adverse maternal side effects nor any increase in the rate of stillbirths, neonatal deaths attributed to SC.

Keywords

• sildenafil
• pregnancy induced hypertension
• iugr
• doppler indices